BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alimta (pemetrexed) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Alimta (pemetrexed)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06462222-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06462222)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2.\nStudy: Immune Checkpoint Inhi
 bitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Me
 tastasis From Solid Tumors\nEstimated primary completion: November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06462222
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06704620-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06704620)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Study of Tislelizumab and Platinum-based Chemotherapy Combination Wit
 h H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic No
 n-Small Cell Lung Cancer\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06704620
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06794645-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06794645)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: Pembrolizumab and Pemetr
 exed for Progressive Chordoma\nEstimated primary completion: 30 November 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06794645
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07122687-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07122687)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chem
 otherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous No
 n-Small Cell Lung Cancer\nEstimated primary completion: 30 November 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07122687
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943820-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06943820)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: AK129 Combination Therapy for Advanced Solid Tumors\nEstimated prim
 ary completion: December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06943820
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890182-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06890182)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for R
 esectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC\nEstimated primary 
 completion: December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06890182
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05456256-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05456256)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers Wi
 th Advanced Lung Adenocarcinoma\nEstimated primary completion: December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05456256
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03786692-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT03786692)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- At
 ezolizumab in Stage IV NSCLC\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03786692
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246110-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06246110)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemothera
 py in Patients With Stage 4 NSCLC\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06246110
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06754644-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06754644)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Evaluate Efficacy\, and Safety of QL2107 Plus Chemo and Co
 mpare With Keytruda in Participants With IV nqNSCLC\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06754644
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585490-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT04585490)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Adaptive ctDNA-Based Personalization of Treatment During Consolidatio
 n Therapy in NSCLC\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04585490
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06809530-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06809530)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2.\nStudy: Intrathecal Dual Check
 point Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Lepto
 meningeal Metastasis\nEstimated primary completion: 1 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06809530
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04185883-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT04185883)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: Sotorasib Activity in Su
 bjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101
 )\nEstimated primary completion: 17 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04185883
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783647-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06783647)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Clinical Trial of LBL-024 Combination Drug in Patients With Advance
 d Solid Tumours[Substudy 01(NSCLC)]\nEstimated primary completion: 24 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 83647
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05253118-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05253118)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: Relapsed or Refractory P
 rimary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System
  (CNS)\nEstimated primary completion: 28 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05253118
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381829-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT07381829)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: A Phase Ib Clinical Stud
 y on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung C
 ancer\nEstimated primary completion: 30 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07381829
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05136846-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT05136846)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: Papaverine in Combination With Chemoradiation for the Treatment of St
 age II-III Non-small Cell Lung Cancer\nEstimated primary completion: 31 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrex
 ed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5136846
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02609776-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT02609776)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: Study of Amivantamab\, a Human Bispecific EGFR and cMet Antibody\, in
  Participants With Advanced Non-Small Cell Lung Cancer\nEstimated primary 
 completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT02609776
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06440954-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06440954)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal
  Metastases\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06440954
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04136535-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT04136535)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride fo
 r Osimertinib-resistant Non-squamous NSCLC\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 etrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04136535
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05805631-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05805631)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant N
 SCLC\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05805631
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT05059522)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Continued Access Study for Participants Deriving Benefit in Pfizer-Sp
 onsored Avelumab Parent Studies That Are Closing\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05059522
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06741644-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06741644)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2.\nStudy: A Phase I/II Study of 
 CS2009 in Participants With Advanced Solid Tumors\nEstimated primary compl
 etion: January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06741644
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06971406-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06971406)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pem
 etrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With L
 eptomeningeal Metastasis\nEstimated primary completion: 1 January 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06971406
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417814-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06417814)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Wi
 thout Osimertinib Compared With Platinum Based Doublet Chemotherapy in Par
 ticipants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell 
 Lung Cancer\nEstimated primary completion: 11 January 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06417814
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06462092-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06462092)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2.\nStudy: Sacituzumab Govitecan 
 and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From H
 er2-negative Breast Cancer\nEstimated primary completion: 15 January 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06462092
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03744793-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT03744793)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: Pemetrexed and Avelumab 
 in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer\nEst
 imated primary completion: 31 January 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03744793
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03760575-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT03760575)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: Pembrolizumab in Combina
 tion With Chemotherapy and Image-Guided Surgery for Malignant Pleural Meso
 thelioma (MPM)\nEstimated primary completion: 1 February 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03760575
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946797-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06946797)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in 
 Combination With Intravenous Ipilimumab and Chemotherapy in Participants W
 ith Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cance
 r (NSCLC)\nEstimated primary completion: 5 February 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06946797
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04077463-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT04077463)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Lazertinib as Monotherapy or in Combination With Amivantam
 ab in Participants With Advanced Non-small Cell Lung Cancer\nEstimated pri
 mary completion: 12 February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04077463
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05443126-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT05443126)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altere
 d Malignancies\nEstimated primary completion: March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05443126
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02817633-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT02817633)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: A Study of TSR-022 in Pa
 rticipants With Advanced Solid Tumors (AMBER)\nEstimated primary completio
 n: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peme
 trexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT02817633
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04956640-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT04956640)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study of LY3537982 in Cancer Patients With a Specific Genetic Mutat
 ion (KRAS G12C)\nEstimated primary completion: April 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04956640
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05410145-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT05410145)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2.\nStudy: A Study of D3S-001 Mon
 otherapy or Combination Therapy in Subjects With Advanced Solid Tumors Wit
 h a KRAS p.G12C Mutation\nEstimated primary completion: April 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05410145
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364917-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06364917)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC\nEstimated pr
 imary completion: 27 April 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06364917
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944470-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06944470)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC\
 nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06944470
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06969612-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT06969612)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study on the Efficacy and Safety of Golidocitinib Combined With Tis
 lelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06969612
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04410796-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT04410796)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers\n
 Estimated primary completion: May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04410796
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05358548-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05358548)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: ATATcH Alternating Treat
 ment Plans for Advanced Cancer\nEstimated primary completion: 1 May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05358548
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07092202-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Alimta (pemetrexed): Phase 4 readout est. (NCT07092202)
DESCRIPTION:Alimta (pemetrexed)\, phase 4\, Non-Small Cell Lung Cancer.\nSt
 udy: Firmonertinib Combined With Intrathecal Injection for the Treatment o
 f EGFR Mutant NSCLC With Leptomeningeal Metastases\nEstimated primary comp
 letion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 emetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07092202
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380636-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT04380636)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followe
 d by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lu
 ng Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)\nEstimated primary completion:
  5 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrex
 ed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4380636
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070440-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07070440)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: DZD6008 Combination Therapy in Patients With Locally Advanced or Me
 tastatic NSCLC With EGFR Mutation (TIAN-SHAN7)\nEstimated primary completi
 on: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetr
 exed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07070440
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated N
 SCLC\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06475300-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06475300)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally
  Advanced or Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Carcin
 oma and Other Solid Tumors\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06475300
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06514027-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06514027)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carryin
 g EGFR Exon 20 Insertion Mutations\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06514027
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04686305-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT04686305)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With a
 nd Without Chemotherapy in Advanced or Metastatic HER2+\, Non-squamous NSC
 LC\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04686305
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845916-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07845916)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based 
 Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer\nE
 stimated primary completion: 30 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07845916
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05198830-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05198830)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Testing the Addition of an Anti-Cancer Drug\, TRC102\, to the Usual C
 hemotherapy Treatment (Pemetrexed\, Cisplatin or Carboplatin) During Radia
 tion Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05198830
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Th
 erapies as Treatments for Participants With Non-Small Cell Lung Cancer (NS
 CLC)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112965-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT05112965)
DESCRIPTION:Alimta (pemetrexed)\, phase 3.\nStudy: An Extension Study in Pa
 rticipants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche 
 Ltd Sponsored Atezolizumab Study (IMbrella C)\nEstimated primary completio
 n: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peme
 trexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05112965
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448754-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06448754)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Volrustomig Priming Regimens Exploratory Phase II Platform Study\nEst
 imated primary completion: 30 July 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06448754
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06784791-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06784791)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Tr
 eatment in Patients With Resectable Non-small-cell Lung Cancer Harboring O
 ncogenic EGFR Mutations (NEOpredict-EGFR)\nEstimated primary completion: 3
 1 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrex
 ed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6784791
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06917079-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT06917079)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: BBO-11818 in Adult Subjects With KRAS Mutant Cancer\nEstimated primar
 y completion: August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06917079
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05001880-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05001880)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: Chemotherapy With or Wit
 hout Immunotherapy for Peritoneal Mesothelioma\nEstimated primary completi
 on: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 metrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05001880
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486817-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07486817)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Beamion 44: A Study to Test How Well Zongertinib is Tolerated by Peop
 le With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given
  in Combination With Chemotherapy With or Without Pembrolizumab\nEstimated
  primary completion: 12 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07486817
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498428-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05498428)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Amivantamab in Participants With Advanced or Metastatic So
 lid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-S
 mall Cell Lung Cancer\nEstimated primary completion: 17 August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05498428
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04253964-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT04253964)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-sm
 all Cell Lung Cancer Patients Treated With Chemo/Immunotherapy\nEstimated 
 primary completion: 1 September 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04253964
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04837716-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270923
DTEND;VALUE=DATE:20270924
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT04837716)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: Ensartinib\, Carboplatin\, Pemetrexed and Bevacizumab for the Treatme
 nt of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cance
 r\nEstimated primary completion: 23 September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04837716
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03233139-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT03233139)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: Safety and Pharmacokinet
 ics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Age
 nts in Japanese Adult Patients With Advanced Malignancies\nEstimated prima
 ry completion: 30 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT03233139
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05335941-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05335941)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: A Phase 2 Study to Evalu
 ate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB12
 2 (Zimberelimab) in Patients With Previously Treated Advanced or Metastati
 c MTAP Deficient Urothelial Carcinoma\nEstimated primary completion: 30 Se
 ptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetre
 xed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05335941
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793179-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT03793179)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as Fir
 st Line Treatment and Maintenance in Non-small Cell Lung Cancer\nEstimated
  primary completion: 30 September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03793179
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561685-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT06561685)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of LY4050784 in Participants With Advanced or Metastatic Soli
 d Tumors\nEstimated primary completion: October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06561685
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05765084-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT05765084)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2.\nStudy: Integration of the PD-
 L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-
 based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma\
 nEstimated primary completion: October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05765084
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05012254-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05012254)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV
  Lung Cancer With Brain Metastases\nEstimated primary completion: 15 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05012
 254
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05118854-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05118854)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplat
 in or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB 
 Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation\nEstim
 ated primary completion: 20 October 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05118854
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309952-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07309952)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Posi
 tive NSCLC\nEstimated primary completion: 31 October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07309952
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154368-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07154368)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive P
 atients Previously Treated With ROS1-TKIs.\nEstimated primary completion: 
 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peme
 trexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07154368
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04162015-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT04162015)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: A Study of Nivolumab and
  Chemotherapy Followed by Surgery for Mesothelioma\nEstimated primary comp
 letion: November 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04162015
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772623-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06772623)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) T
 elisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhib
 itor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC 
 With No Prior Treatment for Advanced Disease\, and No Actionable Genomic A
 lterations\nEstimated primary completion: November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06772623
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06901817-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06901817)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolu
 mab Via Intraventricular Injection for the Treatment of Refractory Non-squ
 amous Non-small Cell Lung Cancer with Leptomeningeal Metastases\nEstimated
  primary completion: November 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06901817
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04605770-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT04605770)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: Pemetrexed\, Cisplatin W
 ith Soft Tissue Sarcoma\nEstimated primary completion: 1 November 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04605770
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04297605-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT04297605)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: Study of Pembrolizumab and Single Agent Chemotherapy as First Line Tr
 eatment for Patients With Locally Advanced or Metastatic Non-small Cell Lu
 ng Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Statu
 s of 2\nEstimated primary completion: 30 November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04297605
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06142617-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06142617)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanc
 ed NSCLC Patients With EGFR Exon 21 Point Mutation.\nEstimated primary com
 pletion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06142617
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431270-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT05431270)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Dose Escalation/Expansion Study of Mavrostobart (PT199)\, an Anti-C
 D73 mAb\, Administered Alone and in Combination With a PD-1 Inhibitor or C
 hemotherapy (the MORNINGSTAR Study)\nEstimated primary completion: Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054312
 70
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846358-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07846358)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: This is a Multicenter\, Open-label\, Phase I/II Study to Explore th
 e Safety\, Tolerability\, Pharmacokinetics (PK)\, and Preliminary Efficacy
  of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.\nEsti
 mated primary completion: December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07846358
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672068-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06672068)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patient
 s With Mutated Epidermal Growth Factor Receptor NSCLC\nEstimated primary c
 ompletion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06672068
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663306-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT06663306)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Lep
 tomeningeal Metastases in NSCLC\nEstimated primary completion: 30 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0666330
 6
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06762080-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06762080)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2.\nStudy: Intrathecal Combinatio
 n of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4
  (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
 \nEstimated primary completion: 30 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06762080
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07004244-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT07004244)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: Application of KRAS Vacc
 ine in the Treatment of KRAS-mutated Malignancies\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07004244
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06969027-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06969027)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: JS207Combined With Chemotherapy in First-line Treatment of Advanced N
 SCLC\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06969027
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681195-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05681195)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: Zanubrutinib With Pemetr
 exed to Treat Relapsed/Refractory Primary and Secondary Central Nervous Sy
 stem (CNS) Lymphomas\nEstimated primary completion: February 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05681195
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415031-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07415031)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: A Solid Tumor Study for 
 Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studi
 es\nEstimated primary completion: 16 February 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07415031
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824792-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Alimta (pemetrexed): Phase 4 readout est. (NCT06824792)
DESCRIPTION:Alimta (pemetrexed)\, phase 4.\nStudy: Optimal Standard Treatme
 nt Selection for Solid Tumor Patients by Biologically-informed Multi-agent
  System\nEstimated primary completion: 29 February 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06824792
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405190-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07405190)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC\nEstimate
 d primary completion: 1 March 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07405190
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586202-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280302
DTEND;VALUE=DATE:20280303
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07586202)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemothe
 rapy in Participants With Resectable EGFR-Mutated NSCLC\nEstimated primary
  completion: 2 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07586202
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871214-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07871214)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Assess The Safety and Tolerability of Pumitamig-Based Ther
 apy Administered Before Surgery in Participants With Early-Stage Non-Small
  Cell Lung Cancer (ROSETTA Lung-220)\nEstimated primary completion: 15 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07871
 214
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07458347-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT07458347)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Par
 ticipants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncoge
 ne Homolog (KRAS) Mutation\nEstimated primary completion: April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07458347
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551778-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07551778)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Allogeneic NK Cell Therapy Combined With Standard Maintenance Treat
 ment in Advanced Solid Tumors\nEstimated primary completion: April 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07551778
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441045-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06441045)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: Double Dose of Third-gen
 eration EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-g
 eneration EGFR-TKI in Patients With LM Progression Following the Treatment
  of Routine Dose of Third-generation EGFR-TKI\nEstimated primary completio
 n: 1 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peme
 trexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06441045
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07383116-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07383116)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus 
 Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanc
 ed Nonsquamous Non-Small Cell Lung Cancer\nEstimated primary completion: 1
 0 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetre
 xed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07383116
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839105-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT06839105)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in
  Patients With Advanced Malignancies\nEstimated primary completion: 30 Apr
 il 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06839
 105
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128303-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT07128303)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: Study of GS-5319 Given A
 lone or in Combination in Adults With Solid Tumors\nEstimated primary comp
 letion: May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 etrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07128303
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06861218-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06861218)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy
  for EGFR-positive NSCLC Leptomeningeal Metastases\nEstimated primary comp
 letion: May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 etrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06861218
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268210-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06268210)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With
  EGFR-mutated Resectable Non-small Cell Lung Cancer\nEstimated primary com
 pletion: May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 metrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06268210
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07234058-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07234058)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: Trial Assessing Fianlima
 b Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Pat
 ients With Pleural Mesothelioma\nEstimated primary completion: May 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07234058
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744529-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280528
DTEND;VALUE=DATE:20280529
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07744529)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-M
 utated Lung Adenocarcinoma\nEstimated primary completion: 28 May 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07744529
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05502237-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT05502237)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus
  Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non
 -Small Cell Lung Cancer\nEstimated primary completion: June 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05502237
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915037-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07915037)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Evaluation of the Effect of Time of Administration on the Activity on
  First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in
  Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III T
 rial\nEstimated primary completion: July 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07915037
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT03768063)
DESCRIPTION:Alimta (pemetrexed)\, phase 3.\nStudy: A Study in Patients Prev
 iously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored A
 tezolizumab Study\nEstimated primary completion: 5 July 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800587-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05800587)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
 \nEstimated primary completion: 1 August 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05800587
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07157956-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280812
DTEND;VALUE=DATE:20280813
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07157956)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2.\nStudy: CVL006 Combination The
 rapy in Advanced Solid Tumors\nEstimated primary completion: 12 August 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07157956
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492680-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07492680)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: A Study of Navlimetostat
  (BMS-986504) Monotherapy and in Combination With Other Agents in Particip
 ants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Del
 etion (MountainTAP-5)\nEstimated primary completion: 15 August 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07492680
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020065-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07020065)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemipli
 mab Monotherapy in Treatment Naive Older and Frail Patients With Metastati
 c NSCLC With PD-L1 <50%\nEstimated primary completion: September 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07020065
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680764-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07680764)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study To Assess the Safety\, Tolerability\, and Efficacy of Imzokit
 ug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) 
 Versus Pumitamig and PDCT as First-line Treatment for Participants With Lo
 cally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)\nEstimated
  primary completion: 15 September 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07680764
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06057935-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280921
DTEND;VALUE=DATE:20280922
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06057935)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: A Study of Additional Ch
 emotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
 \nEstimated primary completion: 21 September 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06057935
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793942-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280926
DTEND;VALUE=DATE:20280927
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07793942)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: A Clinical Trial of MK-2
 010 Alone and With Other Treatments in Participants With Advanced Solid Tu
 mors (MK-2010-002)\nEstimated primary completion: 26 September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07793942
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06335355-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT06335355)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Phase II/III Study of Adebrelimab in Combination With SHR-8068 an
 d Chemotherapy in Advanced or Metastatic NSCLC Patients\nEstimated primary
  completion: October 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06335355
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01878617-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT01878617)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: A Clinical and Molecular
  Risk-Directed Therapy for Newly Diagnosed Medulloblastoma\nEstimated prim
 ary completion: 13 October 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT01878617
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131319-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT07131319)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III 
 NSCLC\nEstimated primary completion: 31 October 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07131319
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181499-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07181499)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Canc
 er (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI\nEstimate
 d primary completion: November 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07181499
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06097728-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20281116
DTEND;VALUE=DATE:20281117
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06097728)
DESCRIPTION:Alimta (pemetrexed)\, phase 3.\nStudy: MEDI5752 in Combination 
 With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma\nEst
 imated primary completion: 16 November 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06097728
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03715933-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT03715933)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: Phase 1 Study of INBRX-1
 09 in Subjects With Locally Advanced or Metastatic Solid Tumors Including 
 Sarcomas\nEstimated primary completion: December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03715933
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07020221)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Sol
 id Tumors\nEstimated primary completion: December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07020221
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382559-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT05382559)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: A Study of ASP3082 in Ad
 ults With Advanced Solid Tumors\nEstimated primary completion: 31 December
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0538255
 9
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624487-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07624487)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Ad
 enocarcinoma\nEstimated primary completion: 31 December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07624487
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04092283-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT04092283)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Testing the Addition of an Antibody to Standard Chemoradiation Follow
 ed by the Antibody for One Year to Standard Chemoradiation Followed by One
  Year of the Antibody in Patients With Unresectable Stage III Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: 31 December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04092283
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05098132-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT05098132)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study of STK-012 Alone and With Other Treatments in Patients With A
 dvanced Lung Cancer and Other Cancers\nEstimated primary completion: Janua
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05098
 132
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712316-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT06712316)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: Safety\, Efficacy\, and Pharmacokinetics of BNT327 in Combination W
 ith Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA
  Lung-02)\nEstimated primary completion: January 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06712316
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05692999-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT05692999)
DESCRIPTION:Alimta (pemetrexed)\, phase 3.\nStudy: Maintenance Pembrolizuma
 b at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Stud
 y\nEstimated primary completion: January 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05692999
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885709-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07885709)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NS
 CLC\nEstimated primary completion: 1 January 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07885709
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706076-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06706076)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of BH-30643 in Subjects With Locally Advanced or Metastatic
  NSCLC Harboring EGFR and/or HER2 Mutations\nEstimated primary completion:
  31 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 etrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06706076
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335497-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07335497)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2.\nStudy: CR-001 in Adult Partic
 ipants With Locally Advanced or Metastatic Solid Tumors\nEstimated primary
  completion: February 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07335497
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996782-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06996782)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: A Platform Study in Non-Small Cell Lung Cancer (NSCLC)\nEstimated p
 rimary completion: 23 February 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06996782
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472647-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07472647)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: SYS6090 Combination Therapy in Advanced Lung Cancer\nEstimated prim
 ary completion: 28 February 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07472647
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970639-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06970639)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemothe
 rapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor 
 (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Canc
 er (NSCLC) and Brain Metastases\nEstimated primary completion: March 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06970639
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07661173-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07661173)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Prospective Study of Firmonertinib as First-line Adaptive Therapy G
 uided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGF
 R-mutated Non-small Cell Lung Cancer\nEstimated primary completion: 6 Marc
 h 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076611
 73
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699757-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT07699757)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion\nEs
 timated primary completion: April 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07699757
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608731-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT07608731)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: Golcadomide With Pemetre
 xed\, Rituximab\, and Dexamethasone for Relapsed and Refractory CNS Lympho
 mas\nEstimated primary completion: April 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07608731
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514793-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07514793)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: Iparomlimab Plus Tovoril
 imab Combined With Bevacizumab and Chemotherapy as First-Line Treatment fo
 r Advanced Mesothelioma\nEstimated primary completion: April 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07514793
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632327-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06632327)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Comparing Impact of Treatment Before or After Surgery in Patients Wit
 h Stage II-IIIB Resectable Non-small Cell Lung Cancer\nEstimated primary c
 ompletion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06632327
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06835569-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT06835569)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Learn About Study Medicine ALTA3263 in Adults With Advance
 d Solid Tumors With KRAS Mutations\nEstimated primary completion: May 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06835569
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397338-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07397338)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Pati
 ents With Solid Tumors\nEstimated primary completion: May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07397338
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07946848-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07946848)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity o
 f Atebimetinib in Participants With Advanced or Metastatic NSCLC.\nEstimat
 ed primary completion: May 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07946848
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07538193-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Alimta (pemetrexed): Phase na readout est. (NCT07538193)
DESCRIPTION:Alimta (pemetrexed)\, phase na\, Non-Small Cell Lung Cancer.\nS
 tudy: Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for St
 age III Lung Cancer\nEstimated primary completion: May 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07538193
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630416-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290510
DTEND;VALUE=DATE:20290511
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06630416)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: Pemetrexed Response in R
 elation to Tumor Alterations of Gene Status for the Treatment of Patients 
 With Metastatic Urothelial Bladder Cancer and Other Solid Tumors\nEstimate
 d primary completion: 10 May 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06630416
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667076-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290523
DTEND;VALUE=DATE:20290524
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06667076)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Amivantamab in Combination With Lazertinib\, or Amivantama
 b in Combination With Platinum-Based Chemotherapy\, for Common Epidermal G
 rowth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Sm
 all Cell Lung Cancer (NSCLC)\nEstimated primary completion: 23 May 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06667076
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06474455-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06474455)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2.\nStudy: A Phase IB/II Clinical
  Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies 
 in Patients With Advanced Solid Tumors\nEstimated primary completion: June
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0647445
 5
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229339-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07229339)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Res
 ectable\, Stage II-IIIB\, Non-Small Cell Lung Cancer\nEstimated primary co
 mpletion: 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07229339
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT03899155)
DESCRIPTION:Alimta (pemetrexed)\, phase 2.\nStudy: Pan Tumor Rollover Study
 \nEstimated primary completion: 25 August 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633667-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05633667)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Study of Novel Treatment Combinations in Patients With Lung Cancer\nE
 stimated primary completion: September 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05633667
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892953-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT04892953)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Local Consolidative Therapy and Durvalumab for Oligoprogressive and P
 olyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
 \nEstimated primary completion: 30 September 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04892953
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04665206-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20291102
DTEND;VALUE=DATE:20291103
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT04665206)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors\n
 Estimated primary completion: 2 November 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04665206
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771764-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07771764)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Multicenter Exploratory Clinical Study of Iruplaltinib Combined Wit
 h Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamo
 us Non-Small Cell Lung Cancer\nEstimated primary completion: 1 December 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07771764
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03872661-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT03872661)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Neoadjuvant IBI308\, Bevacizumab\, Plus Pemetrexed and Carboplatin Fo
 llowed by Surgery in Unresectable Stage III NSCLC\nEstimated primary compl
 etion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03872661
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06607185-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT06607185)
DESCRIPTION:Alimta (pemetrexed)\, phase 1\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS
  Mutant Solid Tumors\nEstimated primary completion: January 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06607185
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745882-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06745882)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Prospective Trial Assessing Real World Outcomes Response to Pembro in
  Black Patients w/ NSCLC\nEstimated primary completion: January 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06745882
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800015-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300116
DTEND;VALUE=DATE:20300117
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT05800015)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Trial to Learn How the Combination of Fianlimab With Cemiplimab a
 nd Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treati
 ng Adult Patients With Advanced Non-small Cell Lung Cancer\nEstimated prim
 ary completion: 16 January 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05800015
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662395-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300124
DTEND;VALUE=DATE:20300125
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT07662395)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: 24 January 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07662395
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04267848-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT04267848)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Testing the Addition of a Type of Drug Called Immunotherapy to the Us
 ual Chemotherapy Treatment for Non-small Cell Lung Cancer\, an ALCHEMIST T
 reatment Trial (Chemo-IO [ACCIO])\nEstimated primary completion: 31 Januar
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT042678
 48
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05067283-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300225
DTEND;VALUE=DATE:20300226
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT05067283)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: A Study of Calderasib (M
 K-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)\nEstimated prim
 ary completion: 25 February 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05067283
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05719558-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Alimta (pemetrexed): Phase 1 readout est. (NCT05719558)
DESCRIPTION:Alimta (pemetrexed)\, phase 1.\nStudy: A Study of ASP1002 in Ad
 ults for Treatment of Solid Tumors\nEstimated primary completion: 30 April
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0571955
 8
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05061550)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung 
 Cancer\nEstimated primary completion: 28 May 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822542-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07822542)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy 
 With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Li
 ne Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung 
 Cancer\nEstimated primary completion: 31 May 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07822542
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775040-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07775040)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherap
 y for Bulky Stage III NSCLC: A Phase II Trial\nEstimated primary completio
 n: 30 June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peme
 trexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07775040
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561386-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06561386)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chem
 otherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squ
 amous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%\nEstimated p
 rimary completion: 30 July 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06561386
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739966-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07739966)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of DS-3939a in Participants With Solid Tumors\nEstimated pr
 imary completion: 31 July 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07739966
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709585-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07709585)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy f
 or Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Pa
 tients\nEstimated primary completion: 31 July 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07709585
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07873086-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20301010
DTEND;VALUE=DATE:20301011
SUMMARY:Alimta (pemetrexed): Phase na readout est. (NCT07873086)
DESCRIPTION:Alimta (pemetrexed)\, phase na\, Non-Small Cell Lung Cancer.\nS
 tudy: MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mut
 ant NSCLC\nEstimated primary completion: 10 October 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07873086
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109402-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06109402)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resecta
 ble Non-small Cell Lung Cancer\nEstimated primary completion: 1 November 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06109402
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627647-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20301118
DTEND;VALUE=DATE:20301119
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06627647)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemo
 therapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squ
 amous NSCLC\nEstimated primary completion: 18 November 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06627647
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594626-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20301209
DTEND;VALUE=DATE:20301210
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07594626)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2.\nStudy: BMS-986504 in Combinat
 ion With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP
  Deletion\nEstimated primary completion: 9 December 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07594626
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07865910-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT07865910)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Learn the Safety and Efficacy of HLX37 in Combination Wi
 th Chemotherapy for First-line Treatment in Adult Participants With Locall
 y Advanced or Metastatic Non-Small Cell Lung Cancer\nEstimated primary com
 pletion: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07865910
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897188-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07897188)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: ASKC202 Plus Limertinib as the First-line Therapy for Patients With E
 GFRm+/MET+ Locally Advanced or Metastatic NSCLC\nEstimated primary complet
 ion: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07897188
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890493-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07890493)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Mic
 robiota Transplant in Advanced Non-Small Cell Lung Cancer\nEstimated prima
 ry completion: 31 December 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07890493
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507188-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07507188)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Collaborative Clinical-translational Cohort of Amivantamab Plus Lazer
 tinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant\, Loc
 ally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR S
 tudy)\nEstimated primary completion: 31 January 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07507188
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829549-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07829549)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus C
 hemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung C
 ancer Without Actionable Genomic Alterations\nEstimated primary completion
 : April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetre
 xed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07829549
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063745-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20310812
DTEND;VALUE=DATE:20310813
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT07063745)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Compare the Combination of Navlimetostat (BMS-986504) Wi
 th Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Ch
 emotherapy in First-line Metastatic Non-small Cell Lung Cancer Participant
 s With Homozygous MTAP Deletion\nEstimated primary completion: 12 August 2
 031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07063745
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06236438-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT06236438)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: Study to Evaluate Adverse Events\, Optimal Dose\, and Change in Dis
 ease Activity\, With Livmoniplimab in Combination With Budigalimab Plus Ch
 emotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Part
 icipants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
  (NSCLC)\nEstimated primary completion: October 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06236438
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07234877-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07234877)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivones
 cimab/Chemotherapy in NSCLC Brain Mets\nEstimated primary completion: Janu
 ary 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0723
 4877
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789082-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20320129
DTEND;VALUE=DATE:20320130
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT05789082)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: A Study Evaluating the Safety\, Activity\, and Pharmacokinetics of 
 Divarasib as a Single Agent or in Combination With Other Anti-Cancer Thera
 pies in Participants With Previously Untreated Advanced or Metastatic Non-
 Small Cell Lung Cancer With a KRAS G12C Mutation\nEstimated primary comple
 tion: 29 January 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05789082
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07943325-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20320229
DTEND;VALUE=DATE:20320301
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07943325)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-S
 mall Cell Lung Cancer\nEstimated primary completion: February 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07943325
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788912-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20320206
DTEND;VALUE=DATE:20320207
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06788912)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non
 -small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)\nEstimated prim
 ary completion: 6 February 2032. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06788912
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165070-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20320213
DTEND;VALUE=DATE:20320214
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT04165070)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizum
 ab (MK-3475) With or Without Chemotherapy When Used With Investigational A
 gents in Treatment-naïve Participants With Stage IV Non-small Cell Lung C
 ancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)\nEstimated primary completion: 1
 3 February 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peme
 trexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04165070
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab 
 (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors 
 (Hexavalent OX40 Agonist)\nEstimated primary completion: July 2033. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877584-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20331130
DTEND;VALUE=DATE:20331201
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07877584)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: PD-1 Blockade Alone Versus in Combination With Chemotherapy as First 
 Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%\nEst
 imated primary completion: 30 November 2033. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07877584
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720167-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20350801
DTEND;VALUE=DATE:20350802
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07720167)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Cemiplimab for Clinical Stage I\, 2-3.9cm\, Non-Small Cell Lung Cance
 r\nEstimated primary completion: 1 August 2035. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07720167
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005102-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20361130
DTEND;VALUE=DATE:20361201
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT07005102)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Assess Adverse Events\, Change in Disease Activity of In
 travenous Telisotuzumab Adizutecan in Combination With Osimertinib as Firs
 t-Line Treatment in Adult Participants With Locally Advanced Unresectable 
 or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer\nEstima
 ted primary completion: November 2036. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07005102
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096844-2232@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20390401
DTEND;VALUE=DATE:20390402
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06096844)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone f
 or Older Adults With Stage IIIB-IV Lung Cancer\, The ACHIEVE Trial\nEstima
 ted primary completion: 1 April 2039. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06096844
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
